Yes, cohort 2 is complete so the analysis should i
Post# of 72433
"Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks. The trial is anticipated to be completed in 2Q2017."
http://www.cellceutix.com/press-release/2017/...8lelciljue
The immediate advancement to the third cohort tells me that B-UP was safe in the second cohort. Cohort 3 enrollment shouldn't be a problem.
"There is significant interest by new patients wishing to participate in the third (final) cohort once enrollment opens."
http://www.cellceutix.com/press-release/2017/...d-outcomes
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)